President Trump plans to sign an executive order implementing a 'Most Favored Nations' policy for prescription drug pricing, requiring pharmaceutical companies to charge U.S. consumers no more than the lowest price offered in other countries. This could lead to price reductions of 30% to 80% for Medicare Part B drugs. The announcement has caused premarket drops in pharmaceutical stocks like Novo Nordisk, Pfizer, and Johnson & Johnson. While some criticize the feasibility of the order, others support its potential for transparency in drug pricing.
Financial Forecasts
cimu topic folytatasa. Minden fenti temaba vago hozzaszolast szivesen latunk.